Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Bullboard Posts
Post by CannabisHeroon Nov 03, 2019 12:11pm
158 Views
Post# 30302337

High Production Cost + $3B Goodwill=Danger

High Production Cost + $3B Goodwill=Danger ACB's production cost is simply too high and their goodwill is absurd. I feel much safer in low cost producers with supply agreements such as ZENA and HEXO. ZENA is doing the rights offering which has crushed the stock, but it is a well run producer with scale and extremely low cost production. The rights offering is the first step in reducing its debt, and there is a good chance it can renegotiate its senior low cost debt on a quarter or two.

Below is a Seeking Alpha article.

https://seekingalpha.com/instablog/1096367-kelly-jc-brown/5368932-zenabis-global-ltd-rights-offering-mechanics-cash-flow-model-balance-sheet-discussion

What happens if ACB has material impairment charges on its goodwill? I don't know if their huge valuation can be supported.
Bullboard Posts